“The publication of these papers are indicative of how CrownBio continues to further validate the translatability of this model and our commitment to bring to the market novel models that are more ...
Researchers at JAX will immediately begin leveraging CrownBio’s vast research services in oncology and CVMD to generate new insights into therapeutic approaches to target disease.
CrownBio will leverage Jiangsu Qyun Bio-Pharmaceuticals expertise to support the Investigational New Drug Application (IND) and further clinical development of CrownBio’s proprietary 10B10 antibody.
CrownBio will present data on its latest scientific developments including the impact of intestinal microbiota on anti-PD-L1 immunotherapy, the development of primary tumor allograft models for pre...
CrownBio’s clients will now be able to purchase hundreds of products on-line across a portfolio consisting of: antibodies for in vivo and in vitro studies, recombinant proteins and cell lines, immu...
OncoExpress has also become available as a mobile app for both Apple and Android operating systems to enable users to access high level model data from their mobile devices “on-the-go”.
CrownBio has expanded its CVMD services capacity by investing in facilities at the University of Louisiana at Lafayette’s New Iberia Research Center (NIRC), the largest national primate research ce...
MuBase offers a user-friendly experience while searching a large collection of model data, including tumor pathology, genomic characterization, and in vivo pharmacology data with standard of care a...
CrownBio’s models are unparalleled in their translatability and enable clinically translatable evaluation of therapeutics that target not only kidney complications, but also hyperglycemia in diabet...
Thanks to the new XenoBase feature, users will now be able to directly search and interact with dose response curves and IC50 data for over 290 cell lines.
CrownBio will present new data on the development of preclinical solutions for NASH research, a therapeutic area with a high unmet need of models for pharmacological evaluation.
8 of 11
Receive JSR Life Sciences news on your RSS reader.
